Faron Highlighted Positive P-I/II Study (BEXMAB) Results of Bexmarilimab for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes
Shots:
- The P-I/II study evaluating bexmarilimab + SoC in patients with aggressive hematological malignancies of r/r AML & MDS
- The results showed that 3 of 5 patients treated with 6mg/kg bexmarilimab + azacitidine doublet cohort achieved objective responses (CR & mCR), 8 of 15 ORs were observed across all 3 doublet dosing cohorts, 4 of 8 patients across the three doublet dosing cohorts (1/3/6mg/kg) failed SoC hypomethylating agents
- All 3 patients with MDS & prior HMA failure showed ORs (PR, mCR & CR) while4 out of 6 in the triplet dosing cohort treated with azacitidine, venetoclax & bexmarilimab also showed an objective response. The company is expected to advance to the P-II part of the (BEXMAB) study in H2’23 focusing on SoC r/r AML and MDS patients failing HMA
Ref: Globenewswire | Image: Faron
Related News:- Faron Pharmaceuticals Provides Update of Bexmarilimab in P-I/II Study (BEXMAB) for the Treatment of Hematological Malignancies
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
